Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Targeting ARF6 may be effectively prevent melanoma metastasis to lungs

Targeting ARF6 may be effectively prevent melanoma metastasis to lungs

PDL BioPharma fourth quarter total revenues increase to $86.0 million

PDL BioPharma fourth quarter total revenues increase to $86.0 million

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept fourth quarter revenue decreases to $0.1 million

Promyleocytic leukemia gene goes up significantly in post treatment of mTOR inhibitors

Promyleocytic leukemia gene goes up significantly in post treatment of mTOR inhibitors

Spherical nucleic acids could revolutionize biomedicine

Spherical nucleic acids could revolutionize biomedicine

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Castle Biosciences launches MyUvealMelanoma website

Castle Biosciences launches MyUvealMelanoma website

FDA grants orphan drug status to Lentigen’s LG631-CD34 for treatment of glioblastoma multiforme

FDA grants orphan drug status to Lentigen’s LG631-CD34 for treatment of glioblastoma multiforme

DelMar announces second closing of $1.5M in private placement

DelMar announces second closing of $1.5M in private placement

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

Study finds key association between Kallikrein 6 and malignant tumors

Study finds key association between Kallikrein 6 and malignant tumors

ELTD1 biomarker may help diagnose glioma

ELTD1 biomarker may help diagnose glioma

Research: Smaller radiation fields can effectively treat aggressive brain tumors

Research: Smaller radiation fields can effectively treat aggressive brain tumors

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Natural killer cell response detrimental to glioblastoma virotherapy

Natural killer cell response detrimental to glioblastoma virotherapy

Studies explore F-18-FLT PET utility in providing prognostic information for patients with gliomas

Studies explore F-18-FLT PET utility in providing prognostic information for patients with gliomas

Fn14 gene plays a role in growth and spread of non-small cell lung cancer tumors

Fn14 gene plays a role in growth and spread of non-small cell lung cancer tumors

Paper illuminates importance of PKM2 in cancer development and progression

Paper illuminates importance of PKM2 in cancer development and progression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.